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Abstract
Background: Frequent activation of the co-transcriptional factor YAP is observed in
a large number of solid tumors. Activated YAP associates with enhancer loci via
TEAD4-DNA-binding protein and stimulates cancer aggressiveness. Although
thousands of YAP/TEAD4 binding-sites are annotated, their functional importance is
unknown. Here, we aim at further identification of enhancer elements that are
required for YAP functions.
Results: We first apply genome-wide ChIP profiling of YAP to systematically identify
enhancers that are bound by YAP/TEAD4. Next, we implement a genetic approach
to uncover functions of YAP/TEAD4-associated enhancers, demonstrate its
robustness, and use it to reveal a network of enhancers required for YAP-mediated
proliferation. We focus on EnhancerTRAM2, as its target gene TRAM2 shows the
strongest expression-correlation with YAP activity in nearly all tumor types.
Interestingly, TRAM2 phenocopies the YAP-induced cell proliferation, migration, and
invasion phenotypes and correlates with poor patient survival. Mechanistically, we
identify FSTL-1 as a major direct client of TRAM2 that is involved in these
phenotypes. Thus, TRAM2 is a key novel mediator of YAP-induced oncogenic
proliferation and cellular invasiveness.
Conclusions: YAP is a transcription co-factor that binds to thousands of enhancer
loci and stimulates tumor aggressiveness. Using unbiased functional approaches, we
dissect YAP enhancer network and characterize TRAM2 as a novel mediator of
cellular proliferation, migration, and invasion. Our findings elucidate how YAP
induces cancer aggressiveness and may assist diagnosis of cancer metastasis.
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Background
The YAP (YES-associated protein) and its paralog, the transcriptional coactivator with
PDZ-binding motif (TAZ), have attracted increasing attention in the last decade for
their ability to stimulate cell proliferation and their frequent activation in a large num-
ber of solid tumors [1]. These two highly related co-transcription factors function
downstream of the Hippo pathway, an evolutionarily conserved signaling network that
senses cell polarity and regulates adhesion, cell death, and differentiation [2, 3]. The
Hippo pathway is an serine/threonine kinase signaling cascade originally identified in
fruit fly [4, 5] that is known for its involvement in controlling organ size and develop-
ment [6, 7]. In mammals, the Hippo pathway negatively regulates the activity of the
transcriptional co-activators YAP and TAZ. Phosphorylation of YAP and TAZ by the
large tumor suppressor 1 and 2 kinases (LATS1 and LATS2) either gives rise to their
association with the 14-3-3 proteins leading to cytoplasmic sequestration of YAP/TAZ
[8, 9] or to ubiquitin-mediated protein degradation [10].
Accumulating evidence indicate that YAP/TAZ control key determinants of cancer
biology, including cell proliferation and chemotherapeutic drug resistance, and have
significant impact on patient prognosis [11–14]. For example, liver-specific YAP over-
expression in mouse models caused hepatocellular carcinoma [15]. Activated YAP was
also demonstrated to mediate tumor progression, metastasis, and drug resistance in
lung cancer cells [16–19]. Last but not the least, high expression of YAP/TAZ, as well
as their increased nuclear localization, was shown to correlate with poor prognosis in
many cancer types [20–23]. Thus, YAP/TAZ are tightly linked to tumor development
and aggressiveness.
YAP/TAZ appear as a significant central node in cellular signaling. Their activity is
triggered by a wide-variety of cell-intrinsic and extrinsic cues, such as cell density, cell
polarity, mechanical stress, and ligands of G protein-coupled receptors (GPCRs), as well
as changes in cellular energy related to glucose and lipid metabolism [8, 24–27]. Mech-
anistically, unphosphorylated YAP/TAZ are able to translocate to the nucleus, where
they activate gene expression programs by interacting with DNA-binding transcription
factors, most prominently from the TEA domain gene family (TEAD) [28]. While it has
been initially reported that YAP regulates the expression of numerous target genes
through binding to promoters, recent studies have demonstrated that YAP modulates
gene transcription through binding to thousands of distal transcriptional enhancer re-
gions [29–32].
Transcriptional enhancers are functional regulatory DNA elements that activate the
expression of their distant target genes [33]. These elements are highly abundant in
mammalian genomes (in the range of hundreds of thousands), and they are currently
viewed as the main determinants of the spatiotemporal regulation of gene expression.
Enhancers can be predicted indirectly by specific chromatin marks, most notably high
H3K4me1 and H3K27ac, and low H3K4me3 [34]. Mechanistically, enhancers serve as
binding platform for transcription factors that regulate target gene transcription
through chromatin loops. Importantly, the binding of transcription factors to their tar-
get enhancers, however, is not always the direct evidence for enhancer function [35],
and the expression of the so-called enhancer-associated RNA as a result of their activa-
tion better correlates with their activity [36, 37].
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The function of the vast majority of the enhancers is poorly understood, and the lack
of specific knowledge on the rules that govern the interaction between enhancers and
their regulated target genes prevents the prediction of their contribution to phenotypes.
However, recent publications using CRISPR-Cas9-mediated functional genetic screen-
ing approaches paved the way to experimentally dissect key roles of transcriptional en-
hancer networks [38, 39].
To uncover key enhancer functions of YAP, we combined a genome-wide and robust
CRISPR-Cas9-mediated approach for YAP activity by targeting YAP/TEAD4-bound en-
hancers in MCF10A cells with activated YAP overexpression. This assay has identified
a handful of YAP-regulated enhancers required for cellular proliferation. Beyond the
known targets of YAP (i.e., MYC and CCND1), we uncovered TRAM2 (translocation
chain-associated membrane 2) and described its contribution to cellular proliferation,
epithelial to mesenchymal transition (EMT), and cellular migration and invasion, as
well as cancer prognosis. TRAM2 is a component of the translocon, a gated channel
that controls the posttranslational processing of nascent secretory and membrane pro-
teins at the endoplasmic reticulum (ER) membrane [40–42]. We have found that
FSTL-1 is a major client of TRAM2 involved in the YAP-induced, TRAM2-dependent
phenotypes. Collectively, our findings do not only detail a new regulatory mode-of-
function for YAP in tumorigenesis, but also demonstrate the benefits in performing
functional enhancer screens by silencing specific transcriptional activation nodes with-
out affecting the basal expression and potential essentiality of their target genes.
Results
A functional genetic screen for activated YAP-mediated deregulated proliferation
To setup a functional genetic screen for YAP oncogenic activity, we generated a cellular
system based on the non-transformed mammary epithelial cell line MCF10A. We
transduced these cells with constitutively active and inactive YAP variants (YAP5SA and
YAP5SA-S94A, respectively) and control empty vector and examined their morphology
and capacity to form mammospheres. In line with a previous report [29], the expression
of the constitutively active form of YAP (YAP5SA, named here activated YAP), but not
the inactive variant (YAP5SA-S94A, YAPS94A mutation disrupts YAP-TEAD interaction),
changed the epithelial cellular morphology of MCF10A to resemble a mesenchymal
phenotype (EMT) and provoked a transformed phenotype manifested in clonogenic
outgrowth (Additional file 1: Fig. S1A). The mild overexpression of YAP5SA and YAP5-
SA-S94A was confirmed by immunoblot (Additional file 1: Fig. S1A). Importantly, acti-
vated YAP also induced deregulated proliferation (Additional file 1: Fig. S1B), in line
with a previous report [43].
As the most activated YAP/TAZ/TEAD4-bound chromatin regions are located within
enhancers [29], we used an in silico approach to interrogate enhancers in chromatin
immunoprecipitation sequencing (ChIPseq) data of YAP, TEAD4, and TAZ in MDA-
MB-231, a triple-negative breast cancer cell line with known high YAP activity [29].
We identified 2902 predicted enhancer regions containing the TEAD4 motif (Fig. 1a).
We then wished to evaluate the effectiveness of CRISPR-targeting and our enhancer
screen approach in MCF10A-YAP5SA cells (MCF10A cells with activated YAP overex-
pression). For that, we used six designed individual CRISPR vectors to target three
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TEAD4 motifs within the top YAP-bound regions (two sgRNA per motif) and trans-
duced them into MCF10A-YAP5SA cells (Additional file 1: Fig. S1C). Subsequently, we
determined the mutational load inflicted by these vectors and its consequence to YAP-
binding by deep sequencing and ChIP-qPCR, respectively. As anticipated, in all six
cases, the introduction of the TEAD4-motif-targeting CRISPR vectors in MCF10A-
YAP5SA cells, but not the non-targeting control vector (sgRNA-NT), generated muta-
tions with a frequency of more than 50% (Fig. 1b; Additional file 1: Fig. S1D). Most im-
portantly, in all six cases, we also observed selective and effective YAP binding, which
Fig. 1 CRISPR-YAP-enh-lib library design, evaluation, and functional screening. a A schematic representation
of the bioinformatics pipeline for the design of short guide RNAs (sgRNA) for CRISPR-YAP-enh-lib library
construction. b ChIP-qPCR assays were performed to evaluate CRISPR efficiency in blocking YAP-binding to
three selected top YAP-bound regions (Region1 chr19:41729486-41729491; Region2 chr22:41686880-
41686885; Region3 chr1:19336594-19336599). Relative YAP binding was calculated and normalized over
negative control (NC1 and NC2) regions and input. PC, positive control region - promoter of ANKRD1, as
described in [29]. sgRNA-NT is a non-targeting control CRISPR vector. Error bars indicate standard deviation
(SD) calculated from three technical replicates. ***P < 0.005, two-tailed Student’s t test. The pie plots are
mutational profiles of MCF10A-YAP5SA cells transduced with sgRNAs targeting the TEAD4 motif of the
selected regions. c A schematic representation of the setup of the functional screen for YAP enhancers, as
detailed in the material and method section “CRISPR library construction and analysis”. d Results of the
functional screen of YAP enhancers. Scatter plot showing the average LFC (log fold change) of the sgRNA
abundances between T = 20 and T = 0 in both MCF10A-YAP5SA and MCF10A control cells (calculated from 3
biological replicates). Colored in orange are the sgRNAs targeting the YAP5SA (positive controls), blue dots
are the negative control sgRNAs, and the green dots are the selected hits showing reduced abundance
only in MCF10A-YAP5SA cells. e A representative plot for enhancer A, one of the selected hits,
supplemented with genomic information of the targeting sgRNA sites, H3K27ac levels (an active enhancer
marker), YAP and TEAD4 binding in MDA-MB-231 cells, and GRO-seq data of MDA-MB-231 and MCF7 cells.
The black arrows indicate the production of enhancer RNA (eRNA). The information about the other
selected hits is shown in Fig. S2. f Validation of the selected hits by competitive proliferation assays in
MCF10A-YAP5SA and MCF10A control cells. Pie plots indicate the mutation status of MCF10A-YAP5SA cells
transduced with the indicated sgRNAs. NT Ctrl is a non-targeting sgRNA control vector. YAP5SA-KO is an
sgRNA vector targeting YAP5SA. Values from days 6 and 12 were normalized to day 0. Error bars indicate SD
from three biological replicates. ***P < 0.005, two-tailed Student’s t test
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was markedly reduced (> 50%) following TEAD4-motif CRISPR targeting (Fig. 1b).
These results indicate that CRISPR targeting of TEAD4 motifs is both robust and ef-
fective, with an estimated less than 20% false-negative rate for TEAD4 motifs that are
targeted by 2 or more CRISPR vectors per region.
Ensured by an effective approach, we used YAP/TEAD4 binding information to con-
struct a CRISPR-Cas9 vector library (CRISPR-YAP-enh-lib) consisting of 4871 vectors
targeting 2439 regions with 3220 TEAD4 motifs out of the 2902 predicted enhancer re-
gions and including positive controls (CRISPR vectors targeting activated YAP5SA) and
non-targeting negative controls (CRISPR vectors with scramble sgRNAs) (Fig. 1a; Add-
itional file 2: Table S1). We then executed a functional genetic screen as shown in
Fig. 1c. We transduced MCF10A-control and MCF10A-YAP5SA cells with CRISPR-
YAP-enh-lib at a multiplicity of infection (MOI) of ~ 0.3 and drug-selected and cul-
tured the cells for 20 more days. Genomic DNA was isolated from the transduced and
drug-selected cells at the start of the experiment (T = 0) and at day 20 (T = 20). Samples
were subjected to PCR-sequencing analysis to determine the abundance of each CRIS
PR vector. We then computed the changes in abundance between T = 20 and T = 0 for
every CRISPR vector in each cell line (Additional file 1: Fig. S2A; Additional file 3:
Table S2) and performed a differential abundance analysis to identify sgRNAs that
affect MCF10A-YAP5SA, but not MCF10A-Control cells (Fig. 1d). We first confirmed
the robustness of the screen with the vast majority of the negative control sgRNAs
(blue dots) showing no significant change in abundance in both cell lines, while the ma-
jority of the YAP5SA-targeting sgRNAs (YAP5SA-knock out (KO), orange dots) were sig-
nificantly depleted only in MCF10A-YAP5SA cells. To identify the TEAD4-motifs with
potential selective activity in MCF10A-YAP5SA cells, we calculated the average differen-
tial abundance of T20 vs T0 of the 2 most depleted sgRNA vectors for each region
from three biological replicates and compared the difference in both cell lines. Then,
we selected the top ten TEAD4-motif hits (green dots) with selective depletion only in
MCF10A-YAP5SA cells. As expected, positive YAP5SA-targeting sgRNA vectors showed
the strongest effect from all the selected hits (Additional file 4: Table S3). We then used
Global Run-On sequencing (GRO-seq) datasets to filter out enhancer hits that did not
show a significant increase in enhancer-associated RNA (eRNA) levels in MDA-MB-
231 compared with MCF7 cells (possessing high and low YAP activity, respectively
[44–46]) (Fig. 1e; Additional file 4: Table S3; Additional file 1: Fig. S2B). This procedure
pinpointed 7 enhancer regions out of the top 10 selected candidates, which we sub-
jected to a more detailed follow-up analysis.
To further confirm screen results, and the endogenous enhancer activity of the se-
lected YAP-bound regions, we transduced MCF10A-YAP5SA and MCF10A-Control
cells with individual CRISPR vectors (two sgRNAs for each TEAD4-motif) and first
measured mutational load. As expected, we observed high frequency of mutations (60–
90%) induced by all targeting vectors (Fig. 1f; Additional file 1: Fig. S3A). Then, we per-
formed GFP-based growth competition assays to assess the effect of each CRISPR vec-
tor on cellular proliferation. As expected, the YAP5SA-targeting vector suppressed the
proliferation of MCF10A-YAP5SA cells only, while the negative control vector neither
affected MCF10A-YAP5SA nor MCF10A-Control cells (Fig. 1f). Depletion of the ectopi-
cally expressed YAP5SA was verified by western blot (Additional file 1: Fig. S3B). Inter-
estingly, all the seven screen-selected hits significantly compromised the proliferation
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of only MCF10A-YAP5SA cells, albeit with a lower potency compared with the effect of
YAP5SA-targeting vectors (Fig. 1f). Altogether, these results suggest that YAP regulates
cell proliferation via a network of at least 7 TEAD4-bound enhancers, each of which
with a relatively moderate contribution.
A network of genes links activated YAP enhancers to the regulation of cellular
proliferation
We sought to identify the critical functional target gene for each selected YAP enhan-
cer. A major advantage of targeting enhancers as compared to gene bodies is that their
disruption affects the induction but not the basal expression level of the target genes.
In particular, this may have benefits in cases where target genes are essential. We there-
fore transduced MCF10A-YAP5SA cells with individual sgRNA vectors targeting the 7
selected YAP enhancers (two validated sgRNA vectors per enhancer) and control (non-
targeting (NT)). Subsequently, we performed mRNA sequencing and differential ex-
pression analysis to search for down regulated genes located within 1–5 Mbp from the
sgRNA targeting sites (Fig. 2a; Additional file 1: Fig. S4A; Additional file 5: Table S4).
This analysis uncovered potential targets for 6 out of the 7 selected YAP enhancers:
TMEM158, TRAM2, CCND1, KIF18A, MYC, and SLC39A1. The location of every se-
lected enhancer region and its corresponding target gene within the same topologically
associating domain (TAD), as assessed by chromatin structure information from pub-
licly available measurements, support direct genetic interactions (Fig. 2a).
Next, we interrogated the cancer genome atlas (TCGA) database to prioritize enhan-
cer target genes by their expression correlation with a YAP gene signature score calcu-
lated from the expression of 57 genes defined in publication [47]. As anticipated, all
selected target genes displayed significant correlation with YAP gene signature score in
most of the tumor types (Fig. 2b), while nearby flanking genes showed a lower level of
correlation for all enhancer regions (Additional file 1: Fig. S4B), reinforcing our enhan-
cer target gene identification.
YAP-mediated TRAM2 activation via EnhancerTRAM2 is required for YAP-mediated
deregulation of cell proliferation
MYC and CCND1 are well-known targets of YAP [48, 49], and their contribution to
cell proliferation, cell cycle, and cancer progression is well-established [50–56]. Never-
theless, we mapped here enhancer regions that wire YAP activation to the induction of
these two genes. Furthermore, while a functional genetic interaction between YAP and
TRAM2, KIF18A, TMEM158, and SLC39A1 was never reported, the role of
TMEM158, KIF18A, and SLC39A1 in cell proliferation or cancer progression was
already established before [57–62]. In contrast, no such information is available for
TRAM2. TRAM2 is a translocating chain-associated membrane protein component of
the translocon, a gated channel that controls the posttranslational processing of nascent
secretory and membrane proteins at the endoplasmic reticulum (ER) membrane [40–
42]. TRAM2 was shown to interact with SERCA2b, a Ca2+ pump, and that this inter-
action is required for TRAM2 function. However, TRAM2 was never linked to YAP,
cellular proliferation, and human cancer.
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We therefore sought to solidify the functional link between YAP, EnhancerTRAM2 (en-
hancer of TRAM2 gene), TRAM2, and cellular proliferation. We first validated that
TRAM2 mRNA expression was downregulated upon EnhancerTRAM2-KOs (Additional
file 1: Fig. S4C), which is in line with RNA-seq data (Fig. 2a; Additional file 5: Table
S4). Then, we assessed the effect of CRISPR-targeting on the binding of YAP to Enhan-
cerTRAM2 by ChIP-qPCR assay. Indeed, targeting the TEAD4 motif of EnhancerTRAM2
(EnhancerTRAM2-KO; two different sgRNAs) significantly reduced YAP binding to
EnhancerTRAM2, but had no effect on a positive (PC) or two negative (NC) control re-
gions (Fig. 3a). Western blot analyses confirmed the effect of EnhancerTRAM2-KO on
TRAM2 protein expression (Fig. 3b). We therefore examined the ability of ectopically
expressed TRAM2 (TRAM2 OE) in MCF10A-YAP5SA cells to negate the phenotypic
impact of targeting EnhancerTRAM2 on cell proliferation. Western blot analysis in
MCF10A-YAP5SA cells verified the mild ectopic expression of TRAM2 in control (NT)
and EnhancerTRAM2-KO conditions compared to control (Empty OE) (Fig. 3b). This
mild over-expression of TRAM2 was sufficient to compromise the reduction in the
proliferation rate of MCF10A-YAP5SA-EnhancerTRAM2-KO cells (Fig. 3c).
Fig. 2 Target gene identification of the selected YAP enhancers. a Genomic views of the regions of the
selected enhancers. The TAD (topologically associated domains) track represents a heatmap showing the
frequency of chromatin interactions in 5 Kb bins in HMEC cells. The RNASeq/Ensembl track indicates known
protein coding genes colored by the changes in gene expression (calculated as the average of log2 fold
changes in gene expression between cells transduced with two different sgRNAs targeting the
corresponding enhancer and non-targeting control sgRNAs). In gray are genes that did not significantly
change. CTCF, ChIA-PET, and RNA Pol-II tracks were obtained from ENCODE from experiments performed
with MCF7 cells using anti-CTCF and anti-RNA Pol-II, respectively (the color scales encode the number of
reads supporting each interaction). b Heatmap plot showing the Pearson correlation coefficient between
each selected enhancer target gene (a) and the YAP gene signature score in publicly available TCGA
RNASeq samples from human tumors. The number in each tile represents the Pearson correlation
coefficient in each TCGA study between the YAP gene signature score and the selected gene. The color
scale represents the p value of correlation test, adjusted for multiple comparisons using Benjamini-
Hochberg correction (ns, not significant; LowEx, low expression)
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We then postulated that if YAP mediates TRAM2 activation via EnhancerTRAM2, a
physical interaction between TRAM2 promoter and the YAP-bound EnhancerTRAM2
should be expected. Indeed, chromatin conformation capture assays (3C) demonstrated
a direct interaction between EnhancerTRAM2 (E) and TRAM2 promoter (P) (Fig. 3d).
This genomic interaction is specific, as neighboring regions (N1-4) did not show any
specific binding signal to EnhancerTRAM2 (Fig. 3d). The 3C PCR products were verified
by Sanger sequencing (Additional file 1: Fig. S5A). We further observed a decrease in
TRAM2 expression following verteporfin treatment (an inhibitor of the YAP-TEAD
interaction) of MCF10A-YAP5SA and MDA-MB-231 cells (Additional file 1: Fig. S5B).
This indicates that YAP-TEAD association mediates TRAM2 activation via
EnhancerTRAM2.
Lastly, we corroborated the role of TRAM2 in cell proliferation. CRISPR-mediated tar-
geting of TRAM2 indicated an approximately 50% TRAM2 knockout by DNA mutation
and western blotting analyses and a clear inhibitory effect on proliferation in both
MCF10A-YAP5SA and MCF10A cells (Fig. 3e–h; Additional file 1: Fig. S5C). Similar pro-
liferation effect of EnhancerTRAM2-KO and TRAM2-KO was obtained in a second YAP-
activated cellular system (MDA-MB-231, Additional file 1: Fig. S5D). Thus, TRAM2 is the
prime functional target of YAP-mediated proliferation through EnhancerTRAM2.
TRAM2 regulates EMT with increased cell migration and invasion but is insufficient to
induce tumor formation
Since TRAM2 expression showed significant high correlation with the YAP gene signa-
ture score in almost all tumor types (Fig. 2b), and TRAM2 is a component of the trans-
locon at the endoplasmic reticulum (ER), we next decided to investigate changes in
protein expression between MCF10A-TRAM2 (MCF10A cells ectopically expressing
TRAM2), MCF10A-YAP5SA (MCF10A cells ectopically expressing activated YAP), and
MF10A-Control (MCF10A cells ectopically expressing inactivated YAP,YAP5SA-S94A)
cells using mass spectrometry (Fig. 4a, b; Additional file 6: Table S5). As expected, we
observed elevated levels of TRAM2 (blue dot) in MCF10A-YAP5SA and MCF10A-
TRAM2 cells and mild YAP overexpression levels (green dot) only in MCF10A-YAP5SA
cells (Fig. 4a). Globally, we found hundreds of significantly and differentially expressed
proteins (adjusted p value < 0.05 and |log2 fold-change| > 0.5) (288 upregulated and
344 downregulated) in MCF10A-YAP5SA cells compared with control cells, as expected
from YAP function as a master regulator of transcription (Fig. 4a, b; Additional file 6:
Table S5). In contrast, MCF10A-TRAM2 cells induced a much milder global change
(33 upregulated and 69 downregulated, Fig. 4a, b). Interestingly, 26 upregulated and 31
downregulated proteins were shared by both MCF10A-YAP5SA and MCF10A-TRAM2
cells, indicating a significant overlap (Fisher exact test p value of 4.09E−27 and 6.11E
−19, respectively; Fig. 4b). We therefore performed a gene set enrichment analysis
(GSEA), which surprisingly indicated that the strongest enriched category of genes was
linked with an EMT signature in both MCF10-YAP5SA and MCF10A-TRAM2 cells
(Fig. 4c, d). Indeed, VIM, a prominent EMT gene [63, 64], was upregulated in
MCF10A-TRAM2 and MCF10A-YAP5SA cells compared to control cells based on our
proteomics data (Additional file 6: Table S5). This observation was also confirmed by
immunoblot analysis (Additional file 1: Fig. S6A).
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To investigate the contribution of TRAM2 to YAP-induced EMT phenotype, we sup-
pressed its expression (TRAM2-KO) in MCF10A-YAP5SA cells. By mass spectrometry
analysis, we found few differentially expressed genes, of which 21 proteins were down-
regulated and only 3 were upregulated by both knockdowns (Fig. 4e, f; Additional file 7:
Table S6). Interestingly, the strongest shared significant category in both MCF10A-
YAP5SA-TRAM2-KOs gene set enrichment analyses was reduced EMT signaling
(Fig. 4g, h). We confirmed this observation by immunoblot analysis of VIM in
MCF10A-YAP5SA-TRAM2-KOs and control cells (Additional file 1: Fig. S6B). A similar
Fig. 3 TRAM2 is a functional component of the YAP pathway. a ChIP-qPCR assays were used to quantify
YAP-binding to EnhancerTRAM2 (chr6:52409174-52409286) in MCF10A-YAP5SA cells transduced with two
different sgRNAs (1 and 2) targeting the TEAD4 motif within EnhancerTRAM2. A non-targeting sgRNA
(sgRNA-NT) was used as control. Relative YAP binding was calculated and normalized to NC1 and input
(NC1, negative control region1; NC2, negative control region2; PC, positive control region). Error bars
indicate SD from three biological replicates. ***P < 0.005, two-tailed Student’s t test. b Western blot analysis
with anti-TRAM2 antibody using lysates obtained from MCF10A-YAP5SA cells transduced with the indicated
lentiviral vectors. NT, non-targeting sgRNA control. Anti-GAPDH antibody served as loading control. c
Competitive proliferation of MCF10A-YAP5SA cells transduced with the indicated lentiviral vectors. Values on
days 6 and 12 were normalized to day 0. Error bars indicate SD from three biological replicates. ***P < 0.005,
two-tailed Student’s t test. NT, non-targeting sgRNA control; TRAM2 overexpression (TRAM2 OE), and
control vector (Empty OE). d 3C chromatin capture experiments were used to assess the interaction
between EnhancerTRAM2 and the promoter of TRAM2. Genome browser representation of the location for
each primer used in the 3C analysis. A constant primer E (blue arrow) was used to amplify EnhancerTRAM2.
Control regions (N1–N4) were amplified with primers indicated in red arrows, and the TRAM2 promoter
region was amplified with primers indicated in green arrows (P1–P6). An agarose gel image of the PCR
products with the expected sizes (red frame). Sanger sequencing results from the indicated PCR products
are shown in Fig. S5A. e Competitive proliferation assay, as described in c, of TRAM2-KOs in MCF10A-YAP5SA
cells. Values on day 6 (T = 6) and day 12 (T = 12) are normalized to day 0 (T = 0). Error bars indicate SD from
three biological replicates. ***P < 0.005, two-tailed Student’s t test. f The cell populations used in e were
subjected to a western blot analysis using anti-TRAM2 and control anti-HSP90 antibodies. g Competitive
proliferation assay, as described in c, of TRAM2-KOs in MCF10A cells. Error bars indicate SD from three
biological replicates. ***P < 0.005, two-tailed Student’s t test. h The cell populations used in g were
subjected to a western blot analysis using anti-TRAM2 and control anti-HSP90 antibodies
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loss-of EMT signature was also observed in MDA-MB-231-TRAM2-KOs cells, albeit
with a smaller magnitude (Additional file 1: Fig. S6C, D; Additional file 8: Table S7).
Thus, TRAM2 might play a key function in YAP-mediated EMT.
In light of the association between YAP, TRAM2, and EMT, we examined the migra-
tory and invasiveness capacity of MCF10A-TRAM2 cells. Interestingly, in vitro cellular
migration assays indicated that TRAM2 expression induces a similar, albeit with a
lower extent, migratory phenotype as MCF10A-YAP5SA cells (Fig. 5a). Immunoblot
analysis of TRAM2 confirmed VIM induction in MCF10A-YAP5SA and MCF10A-
TRAM2 compared to MCF10A-Control cells (Additional file 1: Fig. S6A). Additionally,
Fig. 4 Proteomics analysis suggests a role for TRAM2 in YAP-induced EMT. a Volcano plots of the
proteomics studies in MCF10A cells transduced with the indicated vectors. The data was compared and
normalized to control cells. Dark dots are the proteins that were significantly upregulated or downregulated
compered to control using a cutoff of absolute LFC > 0.5 and adjusted p value < 0.05. YAP is labeled green
and TRAM2 blue. b Venn diagrams representing the significant overlap of upregulated (Fisher’s exact test p
value 4.09E−27) or downregulated (Fisher’s exact test p value 6.11E−19) proteins between YAP and TRAM2
samples compared with control in a. c Bubble plot summarizing gene set enrichment analysis from the
proteomics data presented in a. Significantly enriched gene sets (FDR < 0.25) in at least one condition were
selected, and the normalized enriched scores were plotted for both samples. Bubble sizes represent the
number of genes in each gene set, while the fill colors represent the FDR values as indicated. d GSEA plots
of the EMT-hallmark molecular signature using the proteomics data described in a. e Volcano plots of
proteomics studies in MCF10A-YAP5SA cells transduced with the indicated vectors. The data was compared
and normalized to control cells (non-targeting sgRNA). Dark dots are the proteins that were significantly
upregulated or downregulated compered to control with cutoff of absolute LFC > 0.5 and adjusted p value
< 0.05. f Venn diagrams representing the overlap of upregulated (Fisher’s exact test p value 6.00E−07) or
downregulated (Fisher’s exact test p value 2.01E−30) proteins between TRAM2-KO1 and TRAM2-KO2
samples compared with control samples in the proteomics studies presented in e. g Bubble plot represents
a gene set enrichment analysis from the proteomics data presented in e. Significantly enriched gene sets
(FDR < 0.25) in at least one condition were selected, and the normalized enriched scores were plotted for
both samples. Bubble sizes represent the number of genes in each gene set, while the fill colors represent
the FDR values as indicated. h GSEA plots of the EMT-hallmark molecular signature using the proteomics
data described in e
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even in the context of the highly migratory MDA-MB-231 cells with activated YAP sig-
naling [44, 45], the ectopic expression of TRAM2 boosted cellular migration (Fig. 5b).
Also, loss of TRAM2 slightly, but significantly, compromised the migratory capacity of
MCF10A-YAP5SA as well as MDA-MB-231 cells (Additional file 1: Fig. S6E, F). To con-
firm our findings in an in vivo setting, we orthotopically transplanted MCF10A-control,
MCF10A-YAP5SA, and MCF10A-TRAM2 cells in the fat pad of immunocompromised
(NOD-scid Il2rynullB2mnull) female mice. Two weeks later, we performed intravital
time-lapse imaging to measure the migratory properties of the transplanted cell popula-
tions. Here too, we observed a strong migratory induction by both activated YAP and
TRAM2 (Fig. 5c). We further complemented the induced EMT phenotype with inva-
siveness tests using a Matrigel-coupled wound-healing assay. Figure 5d and e show that
Fig. 5 TRAM2 stimulates cell migration and invasion. a, b In vitro migration assays of MCF10A and MDA-
MB-231 cells transduced with the indicated lentiviral vectors. Cells were labeled with GFP for tracking cells
under the microscope. Error bars indicate SD from counted cells in each condition (for a: Control: n =
16962; TRAM2: n = 5095; YAP: n = 17421; for b: Control: n = 18448; TRAM2: n = 8219). ***P < 0.005, two-tailed
Student’s t test. c In vivo migration assays of GFP-labeled MCF10A cells transduced with the indicated
lentiviral vectors. Cells were injected into the fat pad of NOD-scid IL2Rgammanull female mice, and 14 days
after transplantation cells were tracked by intravital imaging for at least 6 h. In vivo migration speed was
tracked for cells that could be followed for a minimum of 4 h. Error bars indicate SEM from 1119 control
cells (N = 4 tumors), 680 TRAM2 cells (N = 4 tumors), and 1746 YAP cells (N = 4 tumors) respectively. ***P <
0.005, Welch-corrected two-tailed Student’s t test. d Representative overview images of Matrigel-coupled
wound-healing invasion assays of MCF10A cells transduced with the indicated vectors at 0 and 72 h. e
Wound confluence was calculated using IncuCyte system based on 4 independent Matrigel-coupled
wound-healing invasion assay experiments, as in d. f Representative overview images of mammary tumors
after injection of MCF10A, MCF10A-YAP5SA, and MCF10-TRAM2 cells (GFP labeled) in the mammary fat pad
of female mice 14 days and 35 days after transplantation. Shown are 3D (left-hand panels) and single cross
section images (right-hand panels). Purple, collagen; green, GFP fluorescence from injected labeled cells. g
MCF10A cells were transduced with the indicated lentiviral vectors, and injected into the mammary fat pad
of female NOD-scid IL2Rgammanull mice. Tumor growth kinetics were measured using an external caliper.
Error bars indicate SD (N = 4 tumors per condition)
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MCF10A-TRAM2 cells, like their YAP5SA counterparts, presented a higher invasive
characteristic compared with control. The genetic link between TRAM2 and YAP,
their co-expression in cancer datasets, and the induction of similar phenotypes
(EMT, migration and invasion) prompted us to examine the effect of TRAM2 on
in vivo tumor growth. We therefore injected MCF10A-TRAM2, MCF10A-YAP5SA,
and MCF10A-control cells into the fat pad of immunocompromised mice and
monitored tumor-forming capacity. While MCF10A-YAP5SA cells activated a
powerful oncogenic growth phenotype and induced tumors in mice, as reported be-
fore [29], MCF10A-TRAM2 cells only initiated a transient tumorigenic expansion
that regressed 20 days later (Fig. 5f, g). Altogether, our results demonstrate that
TRAM2 stimulates cell proliferation, migration, and invasion, but is insufficient to
maintain oncogenic growth in vivo. A full-blown tumor growth requires the activa-
tion by YAP of other targets than TRAM2.
FSTL-1 is a key client of TRAM2 in EMT
We next sought to investigate the underling mechanism by which TRAM2 induces cel-
lular migration and invasion. First, we considered a feedback mechanism in which
TRAM2 activates YAP and indirectly induces related phenotypes. To test this option,
we performed ChIP-qPCR experiments using anti-YAP antibody in MCF10A-TRAM2,
YAP5SA, and control cells. While the expected strong and significant increase of YAP-
binding in the PC region (positive control region: the promoter of ANKRD1) was ob-
served in MCF10A-YAP5SA cells, MCF10A-TRAM2 cells were as negative as control
(Fig. 6a). The lack of YAP activation by TRAM2 was confirmed by luciferase-reporter
assays using a YAP-target region (Enhancer E, Fig. 6b). Thus, TRAM2 is likely to act
downstream of YAP pathway. To examine this option, we first studied the effect of ec-
topic expression of TRAM2 and activated YAP (YAP5SA) in MCF10A cells and TRAM2
knockout in MCF10A-YAP5SA cells. Corresponding changes in TRAM2 expression
were confirmed by immunoblot analysis (Additional file 1: Fig. S6A, B). At the mRNA
level, activated YAP induced vast expression changes, as expected from YAP function
as a master regulator of transcription (Fig. 6c, Additional file 1: Fig. S7A; Add-
itional file 9: Table S8), which was in accordance with the changes observed at the pro-
tein level (Fig. 4a, Additional file 1: Fig. S7A). In contrast, very little mRNA expression
changes were detected in MCF10A-TRAM2 cells, as well as by TRAM2-KOs in
MCF10A-YAP5SA cells, suggesting that TRAM2 functions at the posttranscriptional
level (Fig. 6c, Additional file 1: Fig. S7B, C; Additional file 9: Table S8; Additional file 10:
Table S9).
TRAM2 is a component of the translocon, a gated macromolecular channel that cou-
ples mRNA translation of nascent secretory and membrane proteins to translocation
across the endoplasmic reticulum (ER) membrane [40–42]. Thus, TRAM2 may func-
tion as a translational regulator of one or more components of the YAP pathway. We
therefore inferred that the key YAP-relevant targets of TRAM2, at the protein level,
should be upregulated both in TRAM2 and activated YAP expressing MCF10A cells
and downregulated upon TRAM2-KOs in MCF10A-YAP5SA cells. Differential expres-
sion analysis between those conditions identified only two proteins that meet the re-
quirements above (FSTL-1 and LEPRE1/P3H1, Fig. 6d). Translocon proteins recognize
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their clients through a signal peptide (SP) emerging from the N-terminus of newly syn-
thesized proteins [65–67]. Indeed, both FSTL-1 and LEPRE1/P3H1 possess signal pep-
tide, indicating they are likely key direct clients of TRAM2. Interestingly, P3H1 is an
enzyme member of the collagen prolyl hydroxylase family. It localizes to the endoplas-
mic reticulum and its activity is required for proper collagen synthesis and assembly
[68]. This is strongly in line with a previous report that TRAM2 is necessary for colla-
gen type I synthesis [69]. Moreover, it has been reported that collagen contributes to
cancer progression, such as invasion, metastasis [70–72] which is also in line with the
EMT induced by TRAM2. To functionally interrogate FSTL-1 in TRAM2-induced
phenotype, we initially validated our proteomics and RNAseq data using qRT-PCR and
immunoblots, showing that TRAM2-KOs affect FSTL-1 protein levels without altering
its mRNA levels in MCF10A-YAP5SA cells (Fig. 6c, d; Additional file 1: Fig. S7D). To
Fig. 6 FSTL1 links YAP and TRAM2 to EMT. a ChIP-qPCR was used to quantify YAP binding to the indicated
regions. NC1 and PC (promoter of ANKRD1) are negative and positive control regions, respectively. Relative
YAP-binding enrichment was calculated and normalized to NC1 and input. Error bars indicate SD from
three biological replicates. ***P < 0.005, two-tailed Student’s t test. b The indicated cell populations were
subjected to luciferase assays using Enhancer E. Error bars indicate SD from three biological replicates.
***P < 0.005, two-tailed Student’s t test. c Volcano plots of RNA-Seq analyses in MCF10A cells transduced
with the indicated vectors. The data was compared and normalized to control cells (Empty-OE or non-
targeting sgRNA). Dark dots are the genes that were significantly upregulated or downregulated in RNA
level compered to control with cutoff of absolute LFC > 0.5 and adjusted p value < 0.05. YAP is labeled
green and TRAM2 red. d Venn diagrams representing the intersection of proteins that were upregulated in
MCF10A-TRAM2 and MCF10A-YAP5SA cells (raw p value < 0.05 and log2 fold-change > 0.7) and were
downregulated in MCF10A-YAP5SA cells upon TRAM2-KO1 and TRAM2-KO2 (raw p value < 0.05 and log2
fold-change < − 0.7). e Representative overview images of Matrigel-coupled wound-healing invasion assays
of MCF10A-TRAM2 cells transduced with the indicated vectors at 0 and 48 h. f Wound confluence was
calculated using IncuCyte system based on 4 independent Matrigel-coupled wound-healing invasion assay
experiments, as in e. g In vitro migration assays of MCF10A-TRAM2 cells transduced with the indicated
lentiviral vectors. Cells were labeled with GFP for tracking cells under the microscope. Error bars indicate SD
from counted cells in each condition (NT: n = 7303; FSTL1 KO1: n = 7051; FSTL1 KO2: n = 5368). ***P < 0.005,
two-tailed Student’s t test
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solidify this observation, we then validated that TRAM2-KOs affect FSTL-1 protein
level in MDA-MB-231 cells (Additional file 1: Fig. S7E). Next, we knocked FSTL-1 out
in MCF10A-TRAM2 cells and examined cellular migration and invasion. These experi-
ments indicated that FSTL-1 is important for maintaining cellular invasion (Fig. 6e, f)
and migration (Fig. 6g) phenotypes in MCF10A-TRAM2 cells. Reduced FSTL-1 expres-
sion by FSTL-1 KOs was confirmed by western blot (Additional file 1: Fig. S7F). These
results are consistent with the observation that FSTL-1 promotes colorectal cancer me-
tastasis via activating the focal adhesion signaling pathway [73].
High TRAM2 correlates with poor patient survival probability
In light of the key role of TRAM2 in YAP-mediated migration and invasion pheno-
types, we investigated the association of its expression with cancer patient survival from
the TCGA database. This identified a positive correlation between tumor TRAM2-
expression and poor survival probability of patients in 8 TCGA studies. As expected
from TRAM2 being a direct target of YAP, 75% of the studies (6 out 8) that show sur-
vival correlation with TRAM2 expression also display a similar level of correlation with
the YAP gene signature score (Fig. 7a, b). Moreover, in 100% of the TCGA studies
where the YAP gene signature score is significantly associated with poor prognosis,
TRAM2 is significantly elevated in tumors with high YAP gene signature score com-
pared to low (Fig. 7c). Altogether, these data support a key role of TRAM2 as a medi-
ator of YAP-induced tumor aggressiveness and poor patient survival probability.
Discussion
Over the past decades, numerous YAP target genes have been discovered and charac-
terized as critical players in YAP-mediated proliferation and oncogenesis. However, a
comprehensive view of the transcriptional function provoked by YAP that is required
for tumor proliferation and aggressiveness remained largely unknown. The advance in
CRISPR-Cas9 technologies enables us to specifically target regulatory DNA elements
across the non-coding human genome. The development of functional genetic screen-
ing approaches for transcriptional enhancers provides the means to obtain such know-
ledge. We inferred that targeting enhancers, rather than gene bodies, specifically
intervenes with transcription activation, but circumvents the disruption of essential
functions of their target genes that can greatly hamper their identification by functional
genetic screening of coding genes. Indeed, our screen has identified seven YAP-
regulated enhancers and pinpointed their target genes (Figs. 1, 2). Of those, at least
three genes (MYC, CCND1, and KIF18A) are essential for cell viability (DepMap,
https://depmap.org/portal/) and thus unlikely to be selected in comparable conven-
tional CRISPR functional genetic screens targeting coding sequences. Together with
the estimation that the false negative rate discovery of functional YAP regulatory ele-
ments in our assay is below 20% (Fig. 1), we conclude that functional genetic screening
of regulatory DNA elements is a very robust technology to decipher YAP function.
Compared with activated YAP, the biological effect of each identified enhancer on
cell proliferation was relatively small, suggesting that YAP provokes a network of tar-
gets to establish a solid phenotype. Our results indicated that the activation of at least
six genes is required for YAP-mediated proliferation (Figs. 1, 2, and 3). We focused on
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TRAM2 in this manuscript because of its unknown link with YAP and cancer progres-
sion. From the remaining five, only the roles of MYC [50–52] and CCND1 [53–56] as
inducers of cell proliferation and cancer progression in connection with YAP were very
well established. The contribution of TMEM158, KIF18A, and SLC39A1 to cell prolif-
eration or cancer progression was established already [57–62], but how exactly they in-
tegrate in the YAP signaling pathway is currently unknown. Further investigation is
required to explore the exact roles of these genes within the YAP oncogenic signaling
network and to establish their roles in cancer development.
Surprisingly, proteomic analysis indicated a stronger link of TRAM2 to YAP and its
role in promoting an epithelial to mesenchymal transition (EMT) phenotype [29, 43]
(Fig. 4). EMT is associated with cancer resistance and aggressive behavior, and the fact
that TRAM2 plays a causal role in these phenotypes (Figs. 4, 5, and 6) indicates that
TRAM2 is a key determinant in YAP signaling. Gene expression datasets of many dif-
ferent cancer types confirmed this conclusion by pinpointing a strong link between
TRAM2 and YAP gene expression signature, and a strong association with poor cancer
patient survival (Fig. 2b and 7a, b).
Fig. 7 High TRAM2 expression is associated with poor cancer patient survival. a The TCGA Pan-Cancer
cohort was used to correlate the expression of TRAM2 and YAP gene signature score [47] with survival
probability of cancer patients. The heatmap summarizes the results of Cox regression analysis using either
TRAM2 expression (log2(TPM)) or YAP gene signature score. b Kaplan-Meier plots of TCGA studies with
significant survival correlation with both TRAM2 expression and YAP gene signature score. Patients were
classified as high (larger or equal than the median; red line) or low (lower than the median; green line) for
TRAM2 expression (log2(TPM)) and YAP gene signature score. Wald pval, p value of Cox regression
calculated in a; n_high, number of patients in category “high”; n_low, number of patients in category “low.”
Censors were labeled with a black cross. c Boxplots showing TRAM2 expression (log2(TPM)) in patients
classified as high (larger or equal than the median; red dots) or low (lower than the median; green dots)
YAP gene signature score in TCGA studies with significant survival correlation with YAP gene signature
score in a. d A model for YAP-mediated enhancers network uncovered in this manuscript
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TRAM2 functions to translocate proteins from the cytosol into the ER. This trans-
location depends on an N-terminal signal peptide and links subcellular localization to
mRNA translation. The correct docking of a client N-terminal signal peptide stimulates
protein production in a process termed co-translation. We used this feature to identify
TRAM2 clients using mass spectrometry, as loss of TRAM2 should lead to reduced
amounts of its direct client proteins but have no impact on its mRNA levels, and iden-
tified FSTL-1 as a key functional client of TRAM2 and activated YAP. We demon-
strated that the expression of FSTL-1 is required for full-blown induction of cellular
migration and invasion induced by TRAM2. It has been reported that FSTL-1 promotes
EMT [74]. Moreover, FSTL-1 was shown to promote metastasis and chemo-resistance
in esophageal squamous cell carcinoma through NFκB-BMP signaling crosstalk [75]
and to promote colorectal cancer metastasis via activating the focal adhesion signaling
pathway [73]. Nevertheless, while the effect of FSTL-1 on TRAM2-induced EMT was
highly significant, its knockout did not completely abolish migration, clearly indicating
that other TRAM2 direct or indirect clients are required for this process too.
Our experiments using intravital imaging indicated that TRAM2 could recapitulate
the cell invasiveness behavior of activated YAP in vivo. In contrast, TRAM2 was only
sufficient to initiate tumor growth but not to sustain its expansion. This is in line with
our genetic screening results indicating that at least seven different YAP regulatory en-
hancers are required for full oncogenic proliferation. Thus, while our observations
tightly tied TRAM2 to YAP signaling network in cancer, and demonstrated TRAM2’s
link to cancer patients’ survival rates, they also indicated that other important targets of
YAP are required to sustain tumorigenic expansion in vivo. Undoubtedly, the well-
described effects of MYC on global transcription and protein production, CCND1 on
cell cycle transition, and KIF18A on chromatin segregation contribute greatly to YAP-
mediated in vivo tumor expansion. Thus, the experiments described in this manuscript
elucidated a YAP-regulated genetic network of enhancers whose targets form a sub-
stantial role in stimulating tumor proliferation and aggressiveness (Fig. 7d).
Conclusions
Our study provides evidence that YAP is localized to enhancer regions to activate spe-
cific gene programs for cell proliferation, migration, and invasion during tumorigenesis.
We show that YAP controls cell proliferation via at least seven enhancers and their po-
tential target genes (MYC, CCND1, TRAM2, KIF18A, TMEM158, and SLC39A1). We
demonstrate TRAM2 functions as a key novel mediator of YAP-induced oncogenic
proliferation and cellular invasiveness.
Methods
Cell culture
MCF10A and MCF10A-YAP5SA cells were cultured in DMEM/F12 medium (Gibco),
supplemented with 1% penicillin/streptomycin (Gibco), 5% horse serum, EGF 10 ng/ml
(Sigma), insulin 10 μg/ml (Sigma), and hydrocortisone 0.5 μg/ml (Sigma). MDA-MB-
231, MCF-7, and 293 T cells were cultured in DMEM medium (Gibco), supplemented
with 1% penicillin/streptomycin (Gibco) and 10% FCS (Hyclone). For mammosphere
formation assay, 1000 cells cm− 2 were seeded on ultralow-attachment plates (Costar),
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in DMEM/F12 supplemented with 10 ng/ml EGF, 5 μg/ml insulin, 0.5 μg/ml hydrocorti-
sone, 52 μg/ml bovine pituitary extract, and B27 supplement. Mammospheres were
checked after 10 days.
Analysis of GRO-seq data
GRO-seq was performed on MDA-MB-231 and MCF-7 cells as reported before [38].
Sequencing reads were aligned to the human genome (hg19) using bowtie2 [76], and
transcriptional units (TUs) were inferred using HOMER software [77]. Read counts per
TU were calculated using HTseq-count [78]. A total of 76,200 TUs covered by at least
20 reads in at least one sample were detected. TU expression levels were then normal-
ized using quantile normalization to allow comparison between samples. Next, we de-
fined bi-directional TUs as pairs of TUs whose start site is separated by no more than
800 bp and are transcribed on opposite strands (TU+ and TU−). As bi-directional tran-
scription is a hallmark of transcriptional regulatory elements, we refer to these loci as
regulatory enhancer elements.
CRISPR library construction and analysis
We designed a CRISPR library to target the TEAD4 motifs in the potential enhancer
regions. For 2439 of the 2902 regions containing TEAD4 motifs, we found an NGG
PAM in a location that is expected to induce a Cas9 DNA cleavage within a distance of
3 bp with respect to the motif (that is, the cut is expected to occur within the motif or
up to 3 bp from its edges). Overall, we could target 3220 motifs and designed 4871 dis-
tinct sgRNAs, including positive and negative controls. To generate a CRISPR-Cas9
lentiviral library (hereafter referred as CRISPR-YAP-enh-lib), the sgRNAs were cloned
into pLentiCRISPRv2 using Gibson Assembly from an oligonucleotide pool synthesized
by CustomArray Inc. MCF10A and MCF10A-YAP5SA cells were transduced with three
independent lentiviral pools of CRISPR-YAP-enh-lib. After selection with puromycin
(1 mg/L), half of the transduced cells were harvested at day 0, while the remaining cells
were cultured with continuous passaging for 20 days. After 20 days, cells were har-
vested, genomic DNA was isolated and the integrated sgRNAs were PCR-amplified and
submitted for next-generation sequencing (NGS) to quantify their relative abundance.
Sequencing was done using single reads of 65 bp on the Hi-Seq2500 platform (Illu-
mina). Sequencing reads were first trimmed to remove adaptor sequences and then
aligned to the sgRNA library sequences, using cutadapt and bowtie2 software, respect-
ively[76, 79]. Read counts per sgRNA were then calculated using R language. To assess
the relative change between the starting and final cell population, MAGeCK software
was employed using the non-targeting negative control sgRNAs for normalization [80].
For a comparison between the two cellular models, the average log2 fold-change ob-
tained from the three replicates was used.
Luciferase reporter assay
The enhancer E region was PCR amplified from DNA of MCF10A cells and cloned into
downstream of Poly-A of the firefly luciferase reporter gene in the pGL3-promoter
(Promega) vector. For transfection of these plasmids, 1 × 105 of MCF10A-YAP5SA,
MCF10A-Control, MCF10A-TRAM2 cells were seeded in 6-well plates. The next day,
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200 ng of each construct (pGL3-promoter, pGL3-promoter-enhancer/forward, and
pGL3-promoter-enhancer/reverse) were co-transfected with 20 ng of Renilla luciferase
reporter construct using Fugene-6 (Promega) following the manufacturer’s protocol.
Luciferase activity was measured 24 h post-transfection using the dual-luciferase re-
porter assay kit (Promega). Cells were lysed directly on the plate with passive lysis buf-
fer for 15 min at room temperature. Firefly and Renilla luciferase activity was measured
using a Centro XS3 LB960 machine (Berthold technologies).
Lentivirus production and infection
293T cells were seeded at the density of 6 × 106 cells per 10 cm dish 1 day prior to
transfection. Transfection was performed using PEI (Polyethylenimine, Polysciences),
and the medium was refreshed 16 h later. Virus-containing supernatant was collected
48 h post-transfection. Next, virus was filtered through a 0.45 μm membrane (Millipore
Steriflip HV/PVDF), snap-frozen and stored at − 80 °C. MCF10A and MCF10A-YAP5SA
were infected and selected with the proper antibiotics 48 h after transduction for at
least 4 days until no surviving cells remained in an uninfected control plate.
Mutational load analysis generated by sgRNAs
Genomic DNA of MCF10A and MCF10A-YAP5SA cells transduced with sgRNAs was
isolated and the concentration was measured. Five hundred nanograms of the genomic
DNA was used for PCR-amplification of the enhancer region. We performed a two-
step PCR by introducing the P5 adapter sequence in the first PCR and P7 adapters with
the indexes in the second PCR. After the second PCR, the libraries were purified with
CleanNA beads (GC Biotech) and quantified on the 2100 Bioanalyzer using a 7500 chip
(Agilent). Equimolar amounts of each sample were taken for samples ran on the same
lane. Deep sequencing was performed with single reads of 150 bp on the Mi-Seq system
with Mi-Seq reagent v2 Nano kit. Sequenced reads were aligned to the amplified en-
hancer region using Bowtie. Bam files were analyzed to count the number of mutations
(mismatches, insertions, or deletions) identified at each location in the enhancer
regions.
RNA-seq library construction and analysis
Total RNA was isolated using Trisure reagent (Bioline) following the manufacturer’s
protocol. Briefly, cells were lysed in Trisure, precipitated with isopropanol, and dis-
solved in RNase-free water. To generate strand-specific libraries, we used the TruSeq
Stranded mRNA sample preparation kit (Illumina) following the manufacturer’s in-
structions. The sequencing libraries were analyzed on a 2100 Bioanalyzer using a 7500
chip (Agilent) and pooled equimolar into a 10-nM multiplex sequencing pool. Enhan-
cer target gene identification (Fig. 2a), RNA-Seq sequenced reads were aligned to the
human genome (hg19) using TopHat2 [81]. The number of reads mapped to each an-
notated gene was counted using HTseq-count [78] and then converted to RPKMs
(using GENCODE v25 annotations). RPKM levels were further normalized using quan-
tile normalization, and expression levels in each sample relative to the control non-
targeting sample were calculated (in log2 base). The rest of RNA-Seq analysis was done
by first removing adapter sequences using cutadapt and then performing gene
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quantification using Salmon software [82]. Differential expression analysis was per-
formed using R package DESeq2 [83]. Volcano plots and Venn diagrams were made
using R language and packages ggplot2 [84] and nVennR [85].
Genome graphs
For YAP and TEAD4 binding tracks, ChiP-Seq raw reads data from MDA-MB-231 cell
line were downloaded from the Sequence Read Archive (accession SRP055170). Raw
reads from replicates were merged and subsequently adaptor-trimmed and aligned to
the human genome (hg19) using cutadapt and Bowtie2 software [76, 79]. Transcription
factor occupancy was then calculated as fold enrichment relative to control samples
(IgG ChipSeq) using Macs2 software [86]. For GRO-Seq tracks, aligned reads from
GRO-Seq experiments (described above) in MCF-7 and MDA-MB-231 were used to
calculate the genome coverage (normalized for sequencing depth) using BEDtools [87].
Layered H3K27ac tracks were downloaded from UCSC browser using the R package
Gviz [88]. For gene tracks, the latest Ensembl gene annotation for genome assembly
hg19 was used. For TAD tracks, binned (5Kb) chromatin interactions were retrieved
from HiC experiments in HMEC cells [89] (https://hicfiles.s3.amazonaws.com/hiseq/
hmec/in-situ/combined.hic) using Juicer Tools (with option “Vanilla Coverage”
normalization) [90]. For CTCF and RNA Pol-II chromatin interaction tracks, BED for-
matted interactions from ChIA-PET experiments in MCF-7 cells were downloaded
from ENCODE (accessions ENCSR000CAD and ENCSR000CAA) and replicates were
combined using a R language and package Genomic Ranges [91]. Genome graphs in
Fig. 1e and Fig. S1C, S2B were generated in R language using the Gviz package. Gen-
ome graphs in Fig. 2a and Fig. S4A were generated using custom R language with pack-
age ggplot2. Gene expression tracks in Fig. 2a and S4A were generated using log2-fold-
change gene expression from RNA-Seq experiments in enhancer-knockout cell lines
compared to non-targeting infected cells (described above).
TCGA analysis
For gene expression correlation between enhancer target genes and YAP gene expres-
sion signature, gene expression data for the TCGA Pan-Cancer cohort recomputed by
the Toil RSEM pipeline were downloaded as transcripts per million (TPM) from the
XENA browser (https://toil.xenahubs.net/download/tcga_RSEM_gene_tpm.gz). The
downloaded log2 (TPM + 0.001) expression data was used to calculate the Pearson cor-
relation coefficient between each enhancer target gene or nearby gene and a YAP gene
expression signature across all TCGA available studies. YAP gene signature score was
calculated for every sample using the expression of 57 genes defined in publication [47]
employing the ssGSEA method from the R package GSVA [92]. For the YAP gene sig-
nature score calculation, genes with log2 (TPM) lower than − 1 were filter out sample
wise. Only primary tumor samples were considered and combinations of TCGA studies
where the average log2 (TPM) of the gene of interest was lower than − 1 were labeled
as “low expression” and discarded for correlation calculation. Pearson correlation coef-
ficient and correlation test (Bonferroni corrected) were computed using R language.
Survival correlation analyses for TRAM2 expression and YAP activity were done
employing TRAM2 log2 (TPM) and the previously calculated YAP gene signature
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scores using the patient overall survival (OS) time computed in [93] and retrieved from
XENA browser (h t tps : / /pancanat l a s . xenahubs .ne t /download/Surv iva l_
SupplementalTable_S1_20171025_xena_sp.gz). For every TCGA cancer study, overall
survival distribution differences were assessed using Cox regression with R package sur-
vival [94]. For selected TCGA studies, survival probability was plot using the Kaplan-
Meier estimator between samples with low (lower than the median) and high (higher
or equal to the median) TRAM2 expression or YAP gene signature score, using R
language.
Chromatin immunoprecipitation (ChIP) and qPCR
Chromatin immunoprecipitations were performed as previously described [95–97].
Cells were fixed with formaldehyde (1%) for 10 min and subsequently quenched with
glycine. Following that, samples were lysed in 1.5 ml Bioruptor Pico Microtubes and
sonicated for at least 13 cycles of 30 s on, 30 s off using Diagenode Bioruptor Pico. We
used antibodies against YAP (EP1674Y, ab52771, Abcam). For YAP ChIPs, 5 μg of anti-
body was conjugated with 50 μL Protein A magnetic beads. The immunoprecipitated
DNA and input DNA were processed for qPCR to measure the YAP binding to specific
regions by using specific primers. Primers are listed in Table S10.
Chromatin conformation capture (3C) analysis
10 × 106 cells were harvested in PBS for each 3C sample. Cells were centrifuged at
300×g for 5 min at RT and resuspended PBS/10% FBS. Then, cells were incubated with
equal volume of 4% formaldehyde (2% end concentration) for 10 min and quenched
with 2M glycine solution (0.2M end concentration), followed by centrifugation at
300×g for 5 min at 4 °C. Cell pellet was then resuspended in PBS/10% PBS and centri-
fuged at 300×g for 5 min at 4 °C. The supernatant was then discarded and snap-frozen,
stored at − 80 °C. The cell pellet was lysed in 3 mL lysis buffer (50 mM Tris-HCl pH
7.5, 0.5% NP-40, 1% Triton X-100, 150 mM NaCl, 5 mM EDTA, protease inhibitor
cocktail (Roche)) for 1.5 h at 4 °C, followed by centrifugation at 1000×g for 3 min. The
pellet was washed once in 1.2× restriction buffer and resuspended again in 500 μL of
1.2× restriction buffer. 15 μL of 10% SDS was added to the suspension and incubated at
37 °C while shaking at 400 rpm. 75 μL of 20% Triton X-100 was added to the suspen-
sion and incubated at 37 °C while shaking at 400 rpm. The samples were then centri-
fuged at 1000×g for 3 min and resuspended in 500 μL of 1× restriction buffer. The
digestion was performed with addition of 200 U of MboI (NEB) at 37 °C overnight. The
digestion efficiency was assessed the next day on agarose gel. The enzyme was then
inactivated at 65 °C for 20 min and then samples were centrifuged at 1000×g for 3 min
to remove the restriction buffer. The pellet was resuspended in 7mL of 1× ligation buf-
fer, and the ligation was performed with addition of 50 U of T4 DNA ligase (5 U/μl)
(Thermo Scientific) at 16 °C overnight. Again, the ligation efficiency was examined on
agarose gel. De-crosslinking was performed by addition of 30 μL of protease K (Roche)
at 65 °C overnight. To remove residual RNA, 15 μL of RNaseA cocktail (Ambion) was
added to the samples and incubated at 37 °C for 45 min. DNA was recovered by adding
7 mL of isopropanol and 70 μL of NucleoMag® P-Beads (Bioke) and incubated for 30
min at room temperature. The samples were centrifuged for 3 min at 1000×g and
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washed with 80% ethanol twice. Finally, the beads were dried and eluted in 300 μL of
10 mM Tris-HCl pH 7.5. To assess the physical interactions between EnhancerTRAM2
and target regions, we designed a constant primer (E) that amplifies the EnhancerTRAM2
region overlapping the junction created by MboI enzyme. For each assessed region, we
designed two primers (reverse and forward) to examine the interactions with Enhancer-
TRAM2. Finally, PCR products were resolved on 2% agarose gel. To examine the se-
quences of the PCR products, DNA bands were cut, isolated, and sanger-sequenced.
Plasmid cloning
YAP5SA and YAP5SA-S94A lentiviral vectors were sub-cloned from pCMV-FLAG-YAP-
5SA and pCMV-FLAG-YAP-5SA-S94A (obtained from Addgene#27371 and #33103)
into pLenti-hPGK-BlastR (CpG-low)-hEF1(CpG-free) backbone plasmid. TRAM2 open
reading frame was PCR amplified from RNA and cloned into pCDH-CMV-MCS-EF1-
Puro vector (obtained from System Bioscience; CD510B-1). To clone pCDH-H2B-GFP
vector, H2B-GFP was cloned into a pCDH-CMV vector (Agami lab). TRAM2-KOs and
FSTL1-KOs plasmids were cloned by following the protocol from addgene (GeCKO,
zhangLab). The primers are listed in Table S10.
H2B-GFP cell generation and competitive proliferation assay
Cells were infected with pCDH-H2B-GFP virus at a multiplicity of infection (MOI)
of ~ 0.3. Then, GFP positive cells were sorted by FACS. MCF10A, MCF10A-
YAP5SA, and MDA-MB-231 cells were infected with indicated sgRNAs. Separately,
we generated polyclonal MCF10A, MCF10A-YAP5SA, and MDA-MB-231 cells stably
expressing H2B-GFP. GFP expressing cells were mixed in a 1:3 ratio with cells
containing individual sgRNAs. The percentage of GFP-expressing cells was assessed
by flow cytometry at the beginning of the experiment (day 0) and at day 6 and day
12. For every condition, 10,000 events were recorded, and the data were analyzed
using FlowJo software.
Proteomics
For proteome analysis, cells pellets were lysed in boiling guanidine lysis buffer as de-
scribed by Jersie-Christensen et al [98]. Protein concentrations were determined with a
Coomassie (Bradford) Protein Assay Kit (Pierce) according to the manufacturer’s in-
structions. Proteins were digested with Lys-C (Wako, enzyme/protein ratio 1:100) for 2
h at 37 °C, after which samples were diluted to 2M GuHCl and digested overnight with
trypsin (Sigma-Aldrich, enzyme to protein = 1:50). Digestion was quenched by the
addition of trifluoroacetic acid (TFA, 1% final concentration) and peptide samples were
desalted on Sep-Pak C18 cartridges (Waters, Massachusetts, USA). After elution, ali-
quots were collected for proteome analysis. All samples were dried using a SpeedVac
and stored at − 80 °C until LC-MS/MS analysis.
Mass spectrometry and proteome data analysis
Prior to mass spectrometry analysis, peptides were reconstituted in 2% formic acid.
Peptide mixtures were analyzed by nanoLC-MS/MS on an Orbitrap Fusion Tribrid or
Q Exactive HF-X Hybrid Quadrupole-Orbitrap Mass Spectrometer equipped with an
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EASY-nLC 1200 system (Thermo Scientific). Samples were directly loaded onto the
analytical column (ReproSil-Pur 120 C18-AQ, 1.9 μm, 75 μm× 500mm, packed in-
house). Solvent A was 0.1% formic acid/water, and solvent B was 0.1% formic acid/80%
acetonitrile. Samples were eluted from the analytical column at a constant flow of 250
nl/min. For single-shot proteome analysis, a 3h gradient (Q Exactive) or 4h gradient
(Orbitrap Fusion) was employed containing a gradual, non-linear increase from 7% B
to 60% B and finishing with a 15-min wash. Proteome data (RAW files) were analyzed
by Proteome Discoverer (version 2.3.0.523, Thermo Scientific) using Percolator and
standard settings. MS/MS data were searched against the human Swissprot database
(20,417 entries, release 2019_02) with Sequest HT. The maximum allowed precursor
mass tolerance was 50 ppm and 0.06 Da for fragment ion masses in the case of Q Exac-
tive data and 50 ppm/0.6 Da for Orbitrap Fusion data. False discovery rates for peptide
and protein identification were set to 1%. Trypsin was chosen as cleavage specificity
allowing two missed cleavages. Carbamidomethylation (C) was set as a fixed modifica-
tion, while oxidation (M), acetyl (Protein N-term), and deamidation (NQ) were used as
variable modifications. The Proteome Discoverer output file containing LFQ abun-
dances and PSM filtered for Xcorr> 1 was loaded into Perseus (version 1.6.5.0) [99].
Abundances were Log2-transformed, and proteins were filtered for at least two out of
three valid values in both conditions for each comparison. Differential expression ana-
lysis was performed using linear model fitting and empirical Bayes moderated t-statis-
tics from limma R package combined with Benjamini-Hochberg multiple test
correction [100]. Gene Set Enrichment Analysis was performed on the proteomics data
using pre-ranked GSEA with the metric − log10(p value)*sign (LFQ differences) using
GSEA software [101]. Bubble plots and volcano plots were generated using R language
with package ggplot2. Venn diagrams to compare the overlap between MCF10A-
YAP5SA and MCF10A-TRAM2 were generated using the R package nVennR [85]. Sig-
nificantly changed proteins which overlap between MCF10A-YAP5SA and MCF10A-
TRAM2 were calculated using Fisher’s exact test from the GeneOverlap R package.
In vitro migration assay
2.5 × 105 cells were seeded on fibronectin (0.1 mg/mL)-coated glass bottom dishes (35
mm2) in culture medium without phenol red. Experiments were performed 16–24 h
after plating. Time-lapse movies were recorded. Cells were labeled with GFP and were
imaged using 460 nm excitation (10 mW/cm2) for an hour at 1 frame/min.
Migration data were analyzed via a Matlab-based modified Gaussian tracking mixture
model, revised from Amat. F. et al [102]. In brief, the time-lapse images were first proc-
essed for single-cell (nuclei) detection followed by cell segmentation and tracking, via
which coordinates of individual cells over time were recorded and extracted for migra-
tion speed analysis. Average speed was calculated from the accumulated migration dis-
tance divided by the total time.
In vitro invasion assay
The 96-well ImageLock™ plate was coated with 50 μL Matrigel (100 μg/mL) after pre-
cold on ice and incubate the plate in 37 °C for 2 h followed by aspirating the unsolidi-
fied Matrigel. Then, 4 × 104 cells were seeded per well. Next day, the homogeneous
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700–800 μm-wide scratch wounds were made in each well on cell monolayers using a
WoundMaker™ (Essen Bioscience). Matrigel was diluted to 5 mg/mL with cold PBS and
kept on ice to avoid solidification before use. Debris and detached cells were removed
by washing with fresh medium twice and the 96-well plate was kept on ice until the
plate is cold (4 °C) followed by removing the medium and adding 50 μL prepared cold
Matrigel into each well to cover the wound. Put the plate into incubator to solidify the
Matrigel which provides a 3D tissue-like environment for cell invasion assay. Add
100 μL fresh medium to each well and put the plate into IncuCyte. Real-time images
were taken every 2 h for 48 h or 72 h in total. Wound closure was quantified using the
relative wound density metric by the instrument software.
Western blots
Cells were harvested by scraper and lysed with RIPA buffer supplemented with 1×
complete protease inhibitor cocktail (Roche) following the manufacturer’s protocol.
Protein concentrations were determined using a Pierce BCA protein assay kit (Thermo
Scientific). Lysates were separated on SDS-PAGE gels and transferred. Membranes
were immunoblotted with the following antibodies: YAP (ab52771, EP1674Y, abcam; 1:
1000), TRAM2 (ab109176, EPR2658, abcam; 1:5000), FSTL-1 (ab11805, abcam, 1:1000),
Vimentin (550,513, BD Biosciences, 1:2000), HSP90 (610,418, BD Biosciences, 1:5000),
and GAPDH (sc-32,233, Santa Cruz, 1:2000). Protein bands were visualized using cor-
responding secondary antibodies (Dako) and ECL reagent (GE Healthcare).
Mouse experiments
NOD-scid Il2Rgammanull-female mice were obtained from Jackson Laboratories. All
animal experiments were approved by the Animal Welfare Committee of the
Netherlands Cancer Institute (NKI) in accordance with national guidelines. Animals
were maintained in the animal department of NKI, housed in individually ventilated
cages (IVC) under specific pathogen-free (SPF) conditions, and received food and water
ad libitum. Mice were used for experiments between 8 and 25 weeks of age. MCF10A
Control-, MCF10A TRAM2-, and MCF10A YAP- cells labeled expressing H2B-GFP
were transplanted in the fat pad of the 4th mammary gland of 8–12-week old NOD-
scid Il2Rgammanull female mice. For each cell line, 1 × 106 cells diluted in 50 μL sterile
PBS and 50 μL Cultrex PathClear Reduced Growth Factor (RGF) BME, Type 2 (Ams-
bio) were injected under aseptic conditions, while animals were sedated with a 2% iso-
flurane/compressed air mixture. Tumor size was monitored twice a week, and tumors
were used for imaging and further processing 14 or 35 days after injection.
Intravital time-lapse imaging
Tumor-bearing mice were sedated using isoflurane inhalation anesthesia (1.5% isoflur-
ane/compressed air mixture). Tumors were surgically exposed through a skin flap, and
the mouse was placed in a custom-made imaging box. Isoflurane was introduced
through a facemask in the imaging box and ventilated by an outlet on the other side of
the box. Imaging was performed on an inverted Leica SP8 Dive system (Leica, Mann-
heim, Germany) with a MaiTai eHP DeepSee laser (Spectra-Physics) and an InSight X3
laser (Spectra –Physics), using the Leica Application Suite X (LAS X) software. Second
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harmonic generation (Collagen I) and GFP were simultaneously excited using 860 nm
(Mai Tai) and 925 nm (Insight X3) and detected at 400–460 nm and 490–550 nm re-
spectively. First, three-dimensional tile scans of the full visible tumor area were ac-
quired with 2 μm Z-step size. To follow in vivo tumor cell migration, regions of
interest in these tumors were selected from the overview scan and were subsequently
imaged as three-dimensional volumes every 30 min with a Z-step size of 1 μm over a
minimal period of 6 h. All images were acquired with a 25x water immersion objective
(HC FLUOTAR L 25x/0.95W VISIR 0.17, working distance 2.40 mm).
Mice experiment image analysis
Three-dimensional overview tile scans of the tumors were stitched and processed in
the true 3D real-time Rendering LAS X 3D Visualization module (Leica microsystems,
Mannheim, Germany). The time-lapse three-dimensional volumes were corrected for
XYZ-shift using the Huygens Object Stabilizer module (Scientific Volume Imaging). In-
dividual cells were tracked using the MTrack2 plugin in ImageJ (Stuurman, N., Schin-
delin, J., Elliot, E., and Hiner, M., http://imagej.net/MTrack2). Only cells that could be
followed over a minimal period of 4 h were included in the analysis.
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